Possibilities of non-pharmacological correction of intestinal microbiota in patients with non-alcoholic fatty liver disease

2020 ◽  
Vol 0 (5) ◽  
pp. 71-78
Author(s):  
G. D. Fadieienko ◽  
T. A. Solomentseva
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Intestinal Microbiota ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Pharmacological Correction ◽  
Alcoholic Fatty Liver Disease

scholarly journals Consumption of post-fermented Jing-Wei Fuzhuan brick tea alleviates liver dysfunction and intestinal microbiota dysbiosis in high fructose diet-fed mice

RSC Advances ◽  
2019 ◽  
Vol 9 (30) ◽  
pp. 17501-17513
Author(s):  
Xiangnan Zhang ◽  
Qiu Wu ◽  
Yan Zhao ◽  
Alim Aimy ◽  
Xingbin Yang
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Intestinal Microbiota ◽  
Liver Dysfunction ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
High Fructose Diet ◽  
High Fructose ◽  
Alcoholic Fatty Liver Disease

Fuzhuan brick tea can improve non-alcoholic fatty liver disease (NAFLD) and intestinal microbiota imbalance induced by a high fructose diet (HFD) intake in mice.

scholarly journals Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Annette Brandt ◽  
Angélica Hernández-Arriaga ◽  
Richard Kehm ◽  
Victor Sánchez ◽  
Cheng Jun Jin ◽  
...  
Keyword(s):  
Small Intestine ◽  
Liver Disease ◽  
Fatty Liver ◽  
Intestinal Microbiota ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota?

2013 ◽  
Vol 19 (4) ◽  
pp. 331-337 ◽  
Author(s):  
M. Knaapen ◽  
R.S. Kootte ◽  
E.G. Zoetendal ◽  
W.M. de Vos ◽  
G.M. Dallinga-Thie ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Intestinal Microbiota ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice

Gut ◽  
2012 ◽  
Vol 62 (12) ◽  
pp. 1787-1794 ◽  
Author(s):  
Tiphaine Le Roy ◽  
Marta Llopis ◽  
Patricia Lepage ◽  
Aurélia Bruneau ◽  
Sylvie Rabot ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Intestinal Microbiota ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Anja Baumann ◽  
Anika Nier ◽  
Angélica Hernández-Arriaga ◽  
Annette Brandt ◽  
Maria J. Lorenzo Pisarello ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Intestinal Permeability ◽  
Intestinal Microbiota ◽  
Fatty Liver Disease ◽  
Rrna Gene ◽  
Microbiota Composition ◽  
Alcoholic Fatty Liver ◽  
The Impact ◽  
Alcoholic Fatty Liver Disease

AbstractToll-like receptors (TLRs) in the liver compartment have repeatedly been attributed to the development of non-alcoholic fatty liver disease (NAFLD). Knowledge on TLR expression in blood cells and their relation to intestinal microbiota and NAFLD development is limited. Here, we determined TLR expression patterns in peripheral blood mononuclear cells (PBMCs) of NAFLD patients and controls, their relation to intestinal microbiota and the impact of TLRs found altered in NAFLD development. Markers of intestinal permeability in blood and TLR mRNA expression in PBMCs were determined in 37 NAFLD patients and 15 age-matched healthy controls. Fecal microbiota composition was evaluated in 21 NAFLD patients and 9 controls using 16S rRNA gene amplicon sequencing. Furthermore, TLR1−/− and C57BL/6 mice (n = 5–6/group) were pair-fed a liquid control or a fat-, fructose- and cholesterol-rich diet. Intestinal microbiota composition and markers of intestinal permeability like zonulin and bacterial endotoxin differed significantly between groups with the latter markers being significantly higher in NAFLD patients. Expression of TLR1-8 and 10 mRNA was detectable in PBMCs; however, only TLR1 expression, being higher in NAFLD patients, were significantly positively correlated with the prevalence of Holdemanella genus while negative correlations were found with Gemmiger and Ruminococcus genera. TLR1−/− mice were significantly protected from the development of diet-induced NAFLD when compared to wild-type mice. While intestinal microbiota composition and permeability differed significantly between NAFLD patients and healthy subjects, in PBMCs, only TLR1 expression differed between groups. Still, targeting these alterations might be a beneficial approach in the treatment of NAFLD in some patients.

scholarly journals Effect of Chinese Herbal Medicine Mixture 919 Syrup on Regulation of the Ghrelin Pathway and Intestinal Microbiota in Rats With Non-alcoholic Fatty Liver Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Manman Chen ◽  
Jingwei Xing ◽  
Danqing Pan ◽  
Pengfei Gao
Keyword(s):  
Body Weight ◽  
Liver Disease ◽  
Herbal Medicine ◽  
Fatty Liver ◽  
Intestinal Microbiota ◽  
Feed Intake ◽  
Fatty Liver Disease ◽  
Therapeutic Drug ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

As a manifestation of metabolic syndrome in the liver, non-alcoholic fatty liver disease (NAFLD) has become the top cause of liver disease in many countries. Recent studies have shown that intestinal microbiota disorder plays an important role in the occurrence and development of NAFLD and that regulating intestinal microbiota provides a new option for NAFLD treatment. In addition, research indicates that risk of NAFLD increases as body mass index rises, and interventions that reduce body weight and change diet can help to lower the incidence of NAFLD. Studies have found that 919 syrup may effectively treat NAFLD in rats by improving liver function and lipid metabolism and regulating body weight and feed intake, however, its potential toxicity and the specific mechanism by which it controls this disease require further exploration. This study assesses both the toxicity of 919 syrup and its regulatory effect on the appetite-related Ghrelin pathway and intestinal microbiota of rats with NAFLD. Results indicate that 919 syrup has no obvious side-effects on body weight, feed intake, blood glucose level, hepatorenal function, and liver tissue structure of normal rats. Moreover, 919 syrup can reverse abnormal changes to expression of Ghrelin pathway genes related to appetite in both the brain and stomach and repair alterations to the intestinal microbiota in rats with NAFLD. This herbal medicine is a safe and promising therapeutic drug for the treatment of NAFLD.

Sign in / Sign up

Export Citation Format

Share Document